Szczegółowy przewodnik wkrótce
Pracujemy nad kompleksowym przewodnikiem edukacyjnym dla GLP-1 Monthly Cost Calculator. Wróć wkrótce po wyjaśnienia krok po kroku, wzory, przykłady z życia i porady ekspertów.
The GLP-1 Monthly Cost Calculator is a comprehensive financial planning tool that estimates the true out-of-pocket expense for patients taking glucagon-like peptide-1 receptor agonist medications for weight management or type 2 diabetes. It accounts for the dramatic gap between list prices (also called wholesale acquisition cost) and what patients actually pay, factoring in insurance plan design, formulary tier placement, deductible status, coinsurance percentages, manufacturer copay assistance programs, and pharmacy channel (retail versus mail-order versus specialty). As of 2025, the list prices for branded GLP-1 medications range from approximately $900 to $1,350 per month, making them among the most expensive chronic medications in common use. The cost landscape for GLP-1 medications is unusually complex because these drugs sit at the intersection of two different insurance benefit categories: diabetes management (where coverage is generally robust) and weight management (where coverage has historically been excluded from most plans). The same molecule, semaglutide, is sold as Ozempic for diabetes at approximately $935 per month and as Wegovy for obesity at approximately $1,349 per month, with different insurance coverage rules for each. Tirzepatide follows the same pattern with Mounjaro (diabetes) and Zepbound (obesity). This calculator helps patients navigate these distinctions and identify the lowest-cost pathway to treatment. The calculator is used by patients evaluating whether they can afford long-term GLP-1 therapy, by physician offices that need to counsel patients on financial feasibility before prescribing, by employer benefit managers assessing the pharmacy cost impact of adding GLP-1 coverage to their health plans, and by health economists modeling the population-level budget impact of widespread GLP-1 adoption. Given that an estimated 42 percent of American adults meet BMI criteria for anti-obesity medication and that GLP-1 drugs may be taken indefinitely, the financial implications are enormous for the healthcare system. Understanding the true monthly cost is critical because medication adherence is strongly correlated with affordability. Studies show that patients facing monthly out-of-pocket costs above $50 to $100 have significantly higher rates of treatment discontinuation, which in the case of GLP-1 medications leads to rapid weight regain and loss of cardiometabolic benefits. By helping patients identify savings programs, optimal pharmacy channels, and insurance navigation strategies, this calculator serves both a financial and clinical purpose.
Monthly Out-of-Pocket Cost = max((List Price - Insurance Paid Amount - Manufacturer Savings Program Discount), Minimum Copay Floor), where Insurance Paid Amount = List Price x (1 - Coinsurance Rate) after the annual deductible has been met, or Insurance Paid Amount = 0 if the deductible has not been met or the drug is not covered. For a worked example: Wegovy 2.4 mg with a list price of $1,349/month, commercial insurance with a $500 annual deductible (already met), 20% specialty tier coinsurance, and a Novo Nordisk savings card capping copay at $25 for the first 13 fills. Insurance pays $1,349 x 0.80 = $1,079.20. Patient responsibility before savings card = $1,349 - $1,079.20 = $269.80. After savings card: patient pays max($269.80 - $244.80, $25) = $25.00 per month.
- 1Select the specific GLP-1 medication and dose from the dropdown menu. The calculator maintains a current database of list prices for all available formulations: Wegovy (0.25 mg through 2.4 mg), Ozempic (0.25 mg through 2.0 mg), Mounjaro (2.5 mg through 15 mg), Zepbound (2.5 mg through 15 mg), Saxenda (0.6 mg through 3.0 mg), and compounded semaglutide preparations. List prices are updated quarterly from wholesale acquisition cost databases and may vary slightly by pharmacy.
- 2Enter your insurance plan details including plan type (commercial PPO/HMO, Medicare Part D, Medicaid, marketplace/ACA exchange, employer self-funded, or uninsured). Each plan type has different typical coverage rules, formulary structures, and cost-sharing designs. The calculator uses these to estimate your likely tier placement and cost-sharing structure. If you know your specific tier (preferred brand, non-preferred brand, specialty), you can enter it directly for a more accurate estimate.
- 3Input your annual deductible amount and how much of it you have already met this calendar year. This is critical because specialty medications like GLP-1 drugs can cost $1,000 or more per fill, and until your deductible is met you may owe the full list price or a negotiated rate. Many patients starting GLP-1 therapy early in the calendar year face a significant first-month cost shock before their deductible is satisfied. The calculator models this month-by-month across the year.
- 4Indicate whether you have enrolled in or are eligible for a manufacturer savings program. Novo Nordisk offers savings cards for Wegovy and Ozempic that can reduce copays to as low as $0 to $25 per month for commercially insured patients, with maximum annual benefits of $200 to $500 per fill. Eli Lilly offers similar programs for Mounjaro and Zepbound. These programs typically exclude government-insured patients (Medicare, Medicaid, Tricare) and have eligibility periods of 12 to 24 months.
- 5Specify your pharmacy channel preference: retail pharmacy, mail-order pharmacy, or specialty pharmacy. Many insurance plans require specialty pharmacy dispensing for GLP-1 medications, which may involve different copay structures (sometimes lower) but also requires planning ahead for delivery schedules. Some mail-order pharmacies offer 90-day supplies at a discount equivalent to 2 to 2.5 months of retail cost. The calculator compares pricing across channels where data is available.
- 6Review the monthly cost breakdown showing list price, insurance payment, your coinsurance or copay, manufacturer discount, and final out-of-pocket amount. The output also projects your annual total cost, shows when you are likely to hit your out-of-pocket maximum (after which your plan pays 100 percent), and highlights any cost cliffs such as when a manufacturer savings card expires or when you enter the Medicare Part D coverage gap.
- 7Use the comparison feature to see your estimated monthly cost for alternative medications side by side. This helps identify whether switching from Wegovy to Zepbound (or vice versa) or considering compounded semaglutide could meaningfully change your cost. The calculator also flags when a prior authorization is likely required and provides tips for navigating the approval process with your insurance plan.
The list price is $1,349 per month. Insurance covers 80 percent ($1,079), leaving $270 in coinsurance. The manufacturer savings card covers up to $245 of that copay, bringing the patient cost to $25. This savings card typically lasts for 13 four-week fills, after which the patient reverts to the $270 monthly coinsurance.
Without insurance, the patient pays the full retail price. Some pharmacies offer modest cash discounts of 5 to 10 percent, and prescription discount cards like GoodRx may occasionally reduce the price to $850 to $950. Eli Lilly's patient assistance program may provide free medication for patients with household income below 400 percent of the federal poverty level.
Medicare Part D covers Ozempic for the diabetes indication but not for weight loss. The first fill absorbs the remaining deductible, then 25 percent coinsurance applies during the initial coverage phase. Once total drug costs reach the catastrophic threshold ($8,000 in 2025), the patient pays only 5 percent. Manufacturer copay cards cannot be used with Medicare.
Compounded semaglutide is available from compounding pharmacies at a fraction of brand-name pricing because it is produced during an FDA-declared shortage period. Prices vary widely by pharmacy, dosage, and geographic location. Patients should verify their compounding pharmacy is licensed and that the product is tested for potency and sterility. The regulatory status of compounded GLP-1 medications may change as brand-name supply normalizes.
Patients use this calculator during the decision-making process before starting GLP-1 therapy to understand whether the medication fits within their monthly budget. Because these medications are typically taken long-term (potentially for life), even a modest monthly cost difference of $50 to $100 compiles to $600 to $1,200 per year and $6,000 to $12,000 over a decade. Patients who understand their true cost upfront are better positioned to plan financially and are less likely to discontinue treatment due to unexpected expenses.
Physician practices and obesity medicine clinics use cost calculators as part of their prescribing workflow to match patients with the most affordable GLP-1 option given their specific insurance coverage. Many practices employ prior authorization specialists who use cost modeling to determine which medication and indication code combination will generate the lowest patient cost. For example, prescribing semaglutide as Ozempic for a patient with both obesity and prediabetes may cost less than prescribing Wegovy for the same patient, depending on the insurance plan's formulary design.
Employer benefit managers and human resources departments use GLP-1 cost modeling to evaluate the financial impact of adding anti-obesity medication coverage to their employee health plans. With the potential eligible population exceeding 40 percent of the workforce, the per-member-per-month cost impact of GLP-1 coverage is a significant budget consideration. These models weigh the pharmacy cost against projected savings in diabetes treatment, cardiovascular events, orthopedic procedures, and disability claims.
Health policy analysts and insurance actuaries use cost calculators to model the population-level budget impact of GLP-1 medications as adoption rates increase. Projections suggest that if even 10 percent of eligible Americans filled a GLP-1 prescription, the annual pharmacy cost would exceed $100 billion, making cost management through formulary design, step therapy requirements, and value-based contracting a critical issue for the sustainability of both commercial and government insurance programs.
Patients who are transitioning between insurance plans mid-year face a special
Patients who are transitioning between insurance plans mid-year face a special cost challenge because their deductible resets with the new plan, potentially requiring them to pay the full list price again until the new deductible is met. This commonly occurs with job changes, marriage, divorce, or aging onto Medicare at 65. The calculator can model the cost impact of a mid-year plan transition by projecting costs under both the old and new plan parameters and summing them to show the true annual out-of-pocket amount.
Patients with both Medicare and Medicaid (dual-eligible beneficiaries)
Patients with both Medicare and Medicaid (dual-eligible beneficiaries) represent a unique cost scenario because Medicaid typically provides secondary coverage that pays most or all of the Medicare cost-sharing, resulting in near-zero out-of-pocket costs. However, state Medicaid formularies vary widely in their coverage of GLP-1 medications, and some states have imposed prior authorization requirements or preferred drug lists that restrict access. The calculator flags dual-eligible status and adjusts the cost estimate accordingly.
Military veterans who receive care through the Veterans Health Administration
Military veterans who receive care through the Veterans Health Administration (VA) face a different pricing structure because the VA negotiates drug prices through the Federal Supply Schedule, typically obtaining discounts of 40 to 60 percent off list price. VA copays for prescription medications are standardized at $5 to $11 per 30-day supply for most veterans. However, VA formulary committees make independent coverage decisions, and GLP-1 availability varies by VA medical center and regional formulary.
| Medication | Monthly List Price | With Insurance (typical) | With Savings Card | Compounded Alternative |
|---|---|---|---|---|
| Wegovy (semaglutide 2.4 mg) | $1,349 | $150-$350 | $0-$25 | N/A (different brand) |
| Ozempic (semaglutide 1.0 mg) | $935 | $25-$150 | $0-$25 | N/A (different brand) |
| Ozempic (semaglutide 2.0 mg) | $935 | $25-$150 | $0-$25 | N/A (different brand) |
| Mounjaro (tirzepatide 15 mg) | $1,023 | $25-$200 | $0-$25 | Not widely available |
| Zepbound (tirzepatide 15 mg) | $1,060 | $150-$350 | $0-$25 | Not widely available |
| Saxenda (liraglutide 3.0 mg) | $1,349 | $100-$300 | $25-$50 | N/A |
| Compounded Semaglutide | N/A | Not covered | N/A | $150-$300 |
How much does Ozempic or Wegovy cost without insurance?
Without insurance, the retail price for Ozempic ranges from approximately $935 to $1,000 per month and Wegovy costs approximately $1,349 per month as of 2025. These prices apply to patients paying the full cash price at a retail pharmacy. However, several options can reduce this cost: Novo Nordisk offers a patient assistance program for patients with household income below 400 percent of the federal poverty level, some pharmacy discount programs like GoodRx may offer modest savings of 5 to 15 percent, and compounded semaglutide from licensed compounding pharmacies is available at $150 to $300 per month during the FDA-declared shortage period.
Does Medicare cover GLP-1 medications for weight loss?
As of 2025, Medicare Part D coverage for anti-obesity medications expanded following legislative changes. Previously, a longstanding statutory exclusion prevented Medicare from covering drugs prescribed solely for weight loss. The Treat and Reduce Obesity Act provisions changed this for certain FDA-approved anti-obesity medications. However, coverage varies by Part D plan, and patients may face specialty tier cost-sharing of 25 to 33 percent coinsurance. Medicare patients are not eligible for manufacturer copay assistance cards, which means their out-of-pocket costs are generally higher than commercially insured patients until they reach the catastrophic coverage threshold.
Are manufacturer savings cards really free, and how long do they last?
Manufacturer savings cards are not free; they shift the cost from the patient to the pharmaceutical company as a marketing incentive. Novo Nordisk's Wegovy savings card typically covers the patient's copay above $0 to $25 per fill, with a maximum benefit of approximately $200 to $500 per fill, for up to 13 fills (about 12 months). Eli Lilly offers similar programs for Mounjaro and Zepbound. These programs are limited to commercially insured patients and exclude those on government insurance. When the savings card expires, patients face a sudden increase in out-of-pocket cost, which is why financial planning for the post-savings-card period is essential.
Is compounded semaglutide safe and legal?
Compounded semaglutide is legal when produced by a licensed 503A or 503B compounding pharmacy during an FDA-declared drug shortage. As of early 2025, the FDA shortage designation for certain semaglutide formulations has been a subject of regulatory action and legal dispute. Compounded versions are not FDA-approved and do not undergo the same rigorous testing for bioequivalence, purity, and potency as brand-name products. Some compounding pharmacies produce high-quality products with independent testing, while others have faced FDA warning letters for quality violations. Patients considering compounded semaglutide should verify the pharmacy's licensing, request certificates of analysis, and discuss the decision with their prescribing physician.
Why do prices vary so much between pharmacies?
Pharmacy pricing for GLP-1 medications varies because of differences in wholesale purchasing agreements, pharmacy benefit manager (PBM) contracts, dispensing fees, and markup structures. A retail chain pharmacy may price Wegovy at $1,349 while a specialty mail-order pharmacy negotiates a lower acquisition cost and passes some savings to the patient. Additionally, pharmacies in the same chain may charge different prices depending on the patient's insurance plan because PBMs negotiate different contracted rates with different pharmacies. Always check multiple pharmacies and compare your insurance copay against cash-plus-discount-card pricing, because in some cases paying cash with a GoodRx coupon is cheaper than using insurance.
How can I reduce my GLP-1 medication cost?
Several strategies can reduce GLP-1 medication costs. First, enroll in the manufacturer savings program if you have commercial insurance. Second, ask your physician to prescribe the medication under a diabetes indication code if clinically appropriate, as insurance coverage for diabetes is typically better than for weight management. Third, consider mail-order or specialty pharmacy channels that may offer lower copays or 90-day supply discounts. Fourth, if uninsured or underinsured, explore compounded semaglutide from a reputable licensed compounding pharmacy. Fifth, check whether your employer offers a separate obesity benefit or wellness program that subsidizes medication costs. Sixth, appeal insurance denials with supporting clinical documentation, as approximately 30 to 50 percent of initial denials are overturned on appeal.
Do GLP-1 medication costs count toward my out-of-pocket maximum?
Yes, for most ACA-compliant commercial insurance plans, GLP-1 medication copays and coinsurance payments count toward your annual out-of-pocket maximum, which is capped at $9,200 for individual coverage in 2025. Once you reach this maximum, your plan covers 100 percent of eligible costs for the remainder of the year. However, amounts paid through manufacturer savings cards may not count toward the out-of-pocket maximum depending on your plan's copay accumulator or copay maximizer policy. Approximately 20 percent of commercial plans now use copay accumulator programs that exclude manufacturer payments from the deductible and out-of-pocket maximum calculations.
Wskazówka Pro
Before filling your first prescription, call both your insurance company and your pharmacy to get a real-time price quote, because the estimated copay shown by online tools can differ significantly from the actual point-of-sale price. Also check whether your plan uses a copay accumulator program, because if it does, the manufacturer savings card payments will not count toward your deductible or out-of-pocket maximum, meaning you could face a second cost spike when the savings card expires.
Czy wiedziałeś?
The combined annual revenue from GLP-1 medications exceeded $50 billion globally in 2024, making this drug class larger than the entire GDP of more than 100 countries. Novo Nordisk, the maker of Ozempic and Wegovy, briefly became the most valuable company in Europe, surpassing luxury conglomerate LVMH, driven almost entirely by demand for these two medications.